Get started
Merck & Company, Inc.Merck & Company, Inc.Merck & Company, Inc.

Merck & Company, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

MRK chart


Full chart

Key facts today

Merck & Company, Inc. obtained a global license for LM-299, a PD-1/VEGF bispecific antibody, from LaNova Medicines, involving a significant pre-tax charge and potential milestone payments.
Analyze the impactAnalyze the impact

MRK upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪251.75 B‬ USD
Dividend yield (indicated)
3.30%
Price to earnings Ratio (TTM)
20.84
Basic EPS (TTM)
4.79 USD
Net income (FY)
‪365.00 M‬ USD
Revenue (FY)
‪59.87 B‬ USD
Shares float
‪2.53 B‬
Beta (1Y)
0.62

Employees


Employees (FY)
‪72 K‬
Change (1Y)
‪+3 K‬ +4.35%
Revenue / Employee (1Y)
‪831.54 K‬ USD
Net income / Employee (1Y)
‪5.07 K‬ USD

About Merck & Company, Inc.


Sector
Health Technology
CEO
Robert M. Davis
Headquarters
Rahway
Website
merck.com
Founded
1891
FIGI
BBG000BPD168
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MRK news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

MRK highest yielding bonds


MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061
Yield to maturity
7.02%
Maturity date
Dec 10, 2061
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050
Yield to maturity
7.02%
Maturity date
Jun 24, 2050
US58933YBF1
MERCK & CO. 21/51
Yield to maturity
6.93%
Maturity date
Dec 10, 2051
US58933YBA2
MERCK & CO. 20/40
Yield to maturity
6.65%
Maturity date
Jun 24, 2040
US58933YAT2
MERCK CO. 2045
Yield to maturity
6.25%
Maturity date
Feb 10, 2045
MRK4806294
Merck & Co., Inc. 4.0% 07-MAR-2049
Yield to maturity
6.14%
Maturity date
Mar 7, 2049
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042
Yield to maturity
6.14%
Maturity date
Sep 15, 2042
US58933YAJ4
MERCK CO. 13/43
Yield to maturity
6.03%
Maturity date
May 18, 2043
US58933YAV7
MERCK & CO. 19/39
Yield to maturity
5.91%
Maturity date
Mar 7, 2039
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063
Yield to maturity
5.83%
Maturity date
May 17, 2063
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053
Yield to maturity
5.72%
Maturity date
May 17, 2053

Explore more bonds 

Sparks


Curated watchlists where MRK is featured.

See all sparks 

Frequently Asked Questions


The current price of MRK is 98.05 USD — it has decreased by −1.48% in the past 24 hours. Watch Merck & Company, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Merck & Company, Inc. stocks are traded under the ticker MRK.
MRK stock has fallen by −3.05% compared to the previous week, the month change is a 1.10% rise, over the last year Merck & Company, Inc. has showed a −7.31% decrease.
We've gathered analysts' opinions on Merck & Company, Inc. future price: according to them, MRK price has a max estimate of 155.00 USD and a min estimate of 100.00 USD. Watch MRK chart and read a more detailed Merck & Company, Inc. stock forecast: see what analysts think of Merck & Company, Inc. and suggest that you do with its stocks.
MRK reached its all-time high on Jun 25, 2024 with the price of 134.63 USD, and its all-time low was 0.97 USD and was reached on Aug 13, 1970. View more price dynamics on MRK chart.
See other stocks reaching their highest and lowest prices.
MRK stock is 1.82% volatile and has beta coefficient of 0.62. Track Merck & Company, Inc. stock price on the chart and check out the list of the most volatile stocks — is Merck & Company, Inc. there?
Today Merck & Company, Inc. has the market capitalization of ‪248.03 B‬, it has increased by 0.31% over the last week.
Yes, you can track Merck & Company, Inc. financials in yearly and quarterly reports right on TradingView.
Merck & Company, Inc. is going to release the next earnings report on Feb 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MRK earnings for the last quarter are 1.57 USD per share, whereas the estimation was 1.48 USD resulting in a 5.80% surprise. The estimated earnings for the next quarter are 1.81 USD per share. See more details about Merck & Company, Inc. earnings.
Merck & Company, Inc. revenue for the last quarter amounts to ‪16.66 B‬ USD, despite the estimated figure of ‪16.47 B‬ USD. In the next quarter, revenue is expected to reach ‪15.47 B‬ USD.
MRK net income for the last quarter is ‪3.16 B‬ USD, while the quarter before that showed ‪5.46 B‬ USD of net income which accounts for −42.13% change. Track more Merck & Company, Inc. financial stats to get the full picture.
Yes, MRK dividends are paid quarterly. The last dividend per share was 0.81 USD. As of today, Dividend Yield (TTM)% is 3.14%. Tracking Merck & Company, Inc. dividends might help you take more informed decisions.
Merck & Company, Inc. dividend yield was 2.72% in 2023, and payout ratio reached ‪2.07 K‬%. The year before the numbers were 2.52% and 49.02% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 21, 2024, the company has ‪72.00 K‬ employees. See our rating of the largest employees — is Merck & Company, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Merck & Company, Inc. EBITDA is ‪18.66 B‬ USD, and current EBITDA margin is 11.45%. See more stats in Merck & Company, Inc. financial statements.
Like other stocks, MRK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Merck & Company, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Merck & Company, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Merck & Company, Inc. stock shows the sell signal. See more of Merck & Company, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.